Credit Assessment: IPULSE LIMITED

1. Credit Opinion: CONDITIONAL

Reasoning: IPULSE demonstrates a strongly improving financial trajectory with significant deleveraging and growing revenues, but presents material concentration risk and an alarmingly thin cash position relative to its turnover. The company's transformation from a heavily indebted position (negative equity in 2020) to a net asset position of £4.45M by 2025 is commendable. However, the near-zero cash balances and dependency on a single major customer warrant conditional approval with specific covenants attached. Any credit facility should include provisions around customer diversification and minimum cash thresholds.

2. Financial Strength

Balance Sheet Transformation – Significant Improvement

The balance sheet tells a story of dramatic restructuring:

The movement from negative equity of £3.45M in 2020 to positive equity of £4.45M in 2025 indicates a substantial capital restructuring event – likely a debt-for-equity swap or significant shareholder injection (noting Mr Richard Koch's 50-75% ownership). Liabilities have been reduced from £4.34M (2023) to just £308K (2025), representing near-complete deleveraging.

Gearing: The company is now effectively ungeared, with minimal liabilities relative to assets. This provides substantial balance sheet resilience.

Concern: The flat equity position between 2021-2023 (£1.40M) suggests accumulated losses during that period, with profitability only emerging meaningfully in 2024-2025. The 2025 marginal decline in shareholders' funds (£4,475,340 to £4,450,698) should be monitored, though this may reflect foreign currency translation adjustments given USD-denominated trade.

3. Cash Flow Assessment

Critical Vulnerability – Cash Position is Alarmingly Low

The cash position is critically thin. A business with £85M turnover holding only £6,865 in cash at year-end raises serious liquidity concerns. While this may be partially explained by cash held in subsidiary accounts or seasonal working capital patterns, the absolute level provides virtually no buffer for operational disruptions.

Working Capital: The significant improvement in current assets vs. current liabilities ratio (noted in the strategic report) is positive, but without granular working capital breakdown, the quality of current assets (particularly trade debtors) cannot be fully assessed.

Operational Cash Generation: The improvement in gross margin from 20% to 25% suggests better cash conversion potential. However, the growing employee base (286 to 321) and continued R&D investment will require sustained cash generation.

Mitigating Factor: The near-zero debt position means no debt service requirements, reducing ongoing cash demands. The group may also hold cash in subsidiary entities not visible at the consolidated headline level.

4. Monitoring Points

High Priority

• Customer Concentration Risk: The strategic report explicitly identifies dependency on a single ODM customer. Loss of this customer would be catastrophic. Monitor for diversification progress in own-brand SmoothSkin revenues and any new ODM relationships.
• Cash Position: Require monthly cash flow reporting. The £6,865 cash position against £85M turnover is unsustainable as a buffer. Establish minimum cash covenant appropriate to the facility size.
• USD/GBP Exchange Rate Exposure: Majority of trade is USD-denominated whilst reporting in GBP. Monitor hedging effectiveness and margin impact of currency movements.

Medium Priority

• Gross Margin Sustainability: The 5 percentage point improvement (20% to 25%) is significant. Assess whether this is structural or reflects temporary factors (pricing, mix, cost deferral). Any reversion would materially impact cash generation.
• Regulatory Compliance: As a medical device manufacturer, loss of regulatory certifications would immediately impact revenue. Monitor for any compliance issues across jurisdictions.
• Related Party Transactions: Given Mr Koch's dominant shareholding (50-75%), monitor for transactions that may preference shareholder interests over creditor protection.

Ongoing

• Employee Retention: Growing headcount (286 to 321) in a specialist R&D function represents both an asset and a risk – key person dependency in clinical and development functions.
• Supply Chain Resilience: Monitor inventory levels and supplier diversification given acknowledged supply chain disruption risks.
• Group Structure: With seven subsidiaries noted in the filing, inter-company balances and cash positioning across the group should be understood.